PMVP.OQ
Latest Trade
37.63USDChange
1.44(+3.98%)Volume
22,101Today's Range
-
39.3052 Week Range
-
62.41As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 36.19 |
|---|---|
Open | 36.78 |
Volume | 22,101 |
3M AVG Volume | 3.35 |
Today's High | 39.30 |
Today's Low | 36.71 |
52 Week High | 62.41 |
52 Week Low | 31.06 |
Shares Out (MIL) | 44.77 |
Market Cap (MIL) | 1,620.36 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Pmv Pharmaceuticals Reports QTRLY Loss Per Share $1.46
PMV Pharmaceuticals Inc Shares Open 94.4% Above IPO Price In Debut On Nasdaq
PMV Pharma Announces Pricing Of Initial Public Offering
PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. It is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.
Industry
Biotechnology & Drugs
Executive Leadership
David H. Mack
President, Chief Executive Officer, Co-Founder, Director
Winston Kung
Chief Financial Officer, Chief Operating Officer
Deepika Jalota
Senior Vice President - Head of Regulatory Affairs
Thomas Davis
Vice President - Biology
Binh Vu
Vice President - Chemistry
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 4.39 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.